Company Overview
Company Type: Private Company
Website: www.findtherapeutics.com
Number of Employees: -
Year Founded: 2020
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Find Therapeutics Inc. operates as a drug development technology company that develops therapies for the treatment of inflammatory and fibrotic rare diseases of the airways, liver, and gastrointestinal systems. It develops GPCR (G protein-coupled receptor) allosteric modulators to treat diseases. The company was incorporated in 2020 and is based in Saint-Laurent, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Douville, Philippe 
CEO & Director
Glanzman, Robert L.
Chief Medical Officer

Key Board Members
Name
Title
Truex, Paul F.
Chairman
Douville, Philippe 
CEO & Director
Antel, Jack 
Member of Clinical Advisory Board
Arnold, Douglas 
Member of Clinical Advisory Board
Auger, Frederic Lemaitre
Director
Bouvier, Michel 
Member of Scientific Advisory Board
Cohen, Jeffrey K.
Member of Clinical Advisory Board
De Seze, Jerome 
Member of Clinical Advisory Board
Freedman, Mark S.
Member of Clinical Advisory Board
Neuville, Pascal 
Director
Rulleau, Laurence 
Director
Sormani, Maria Pia
Member of Clinical Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
7171 Frederick-Banting | Saint-Laurent, QC | H4S 1Z9 | Canada
Phone: 438 399 0175   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
adMare BioInnovations
Jun-08-2020
Minority
-
Seed
CTI Life Sciences
Jun-08-2020
Minority
-
Seed
Domain Therapeutics SA
Jun-08-2020
Minority
-
Seed


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-08-2020
Jun-08-2020
Private Placement
Target
Find Therapeutics Inc.
CTI Life Sciences,Domain Therapeutics SA,adMare BioInnovations

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-05-2023
Executive/Board Changes - Other
Find Therapeutics Appoints Robert L. Glanzman as Chief Medical Officer
Jan-16-2023
Company Conference Presentations
Find Therapeutics Inc. Presents at 6th Annual Neuroscience Innovation Forum - Virtual Week, Jan-16-2023
Jan-09-2023
Company Conference Presentations
Find Therapeutics Inc. Presents at BIO Partnering at JPM 2023, Jan-09-2023
Nov-07-2022
Executive/Board Changes - Other
Find Therapeutics Announces Advisory Board Changes
Aug-01-2022
Executive/Board Changes - Other
Find Therapeutics Inc. Appoints Paul F. Truex as Chairman of the Board


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 15, 2023 01:11 AM
Find Therapeutics Inc.
Find Therapeutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
20
GlobalData

Sep 14, 2023 09:28 PM
Find Therapeutics Inc.
Find Therapeutics Inc
Reports
38
GlobalData

Jun 29, 2023 12:20 AM
Find Therapeutics Inc.
Find Therapeutics Inc
Reports
37
GlobalData

Jun 09, 2023 12:19 AM
Find Therapeutics Inc.
Find Therapeutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
20
GlobalData

Mar 15, 2023 03:10 AM
Find Therapeutics Inc.
Find Therapeutics Inc
Reports
36
GlobalData

Mar 10, 2023 02:56 AM
Find Therapeutics Inc.
Find Therapeutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
19
GlobalData

Dec 14, 2022 07:34 PM
Find Therapeutics Inc.
Find Therapeutics Inc
Reports
36
GlobalData

Dec 10, 2022 03:47 AM
Find Therapeutics Inc.
Find Therapeutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
20
GlobalData

Sep 23, 2022 07:00 PM
Find Therapeutics Inc.
Find Therapeutics Inc
Reports
30
GlobalData

Sep 15, 2022 01:15 AM
Find Therapeutics Inc.
Find Therapeutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
19


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Truex, Paul F.
Chairman
438 399 0175
-

Douville, Philippe 
CEO & Director
438 399 0175
-
pdouville@findtherapeutics.com
Antel, Jack 
Member of Clinical Advisory Board
438 399 0175
-

Arnold, Douglas 
Member of Clinical Advisory Board
438 399 0175
-

Auger, Frederic Lemaitre
Director
438 399 0175
-

Bouvier, Michel 
Member of Scientific Advisory Board
438 399 0175
-

Cohen, Jeffrey K.
Member of Clinical Advisory Board
438 399 0175
-

De Seze, Jerome 
Member of Clinical Advisory Board
438 399 0175
-

Freedman, Mark S.
Member of Clinical Advisory Board
438 399 0175
-

Neuville, Pascal 
Director
438 399 0175
-

Rulleau, Laurence 
Director
438 399 0175
-

Sormani, Maria Pia
Member of Clinical Advisory Board
438 399 0175
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Douville, Philippe 
CEO & Director
438 399 0175
-
pdouville@findtherapeutics.com
Glanzman, Robert L.
Chief Medical Officer
438 399 0175
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
